Articles related to CARDIOVASCULAR DISEASE (CVD)

Recent survey findings reveal that nearly one-third of adults aged 60 and older take daily aspirin for primary prevention of heart disease, despite updated guidelines advising against it for those without prior cardiovascular events.

The introduction of the PREVENT equations could reduce the number of adults eligible for statin therapy by nearly 40%, impacting clinical guidelines and patient care strategies.

A phase 3 trial demonstrates that aficamten improves oxygen utilization during exercise for obstructive HCM patients, indicating its potential to enhance daily functionality and quality of life.

In a phase 2b trial, plozasiran significantly reduced fasting triglyceride levels at 24 weeks in patients with mixed hyperlipidemia, with the 50 mg quarterly dose achieving a mean reduction of 62.4 percentage points. This study highlights the potential of APOC3 inhibition as a therapeutic strategy for lipid management.

This study evaluates the use of statins for primary prevention of cardiovascular diseases in adults aged 75 years and older, demonstrating a significant reduction in CVD incidence without an increase in severe adverse events. These findings provide real-world evidence to guide clinical decision-making in this underrepresented population.

The phase 3 trial of aficamten for symptomatic obstructive hypertrophic cardiomyopathy showed a significant improvement in peak oxygen uptake compared to placebo, with meaningful enhancements in patient-reported outcomes and clinical measures.